

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(12)

Oversættelse af europæisk patentskrift

(10) **DK/EP 3717452 T3**

-
- (51) Int.Cl.: **C 07 C 231/02 (2006.01)** **C 07 C 231/12 (2006.01)** **C 07 C 231/24 (2006.01)**
C 07 C 237/06 (2006.01) **C 07 C 269/04 (2006.01)** **C 07 C 269/06 (2006.01)**
C 07 C 269/08 (2006.01) **C 07 C 271/22 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2024-08-19**
- (80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2024-06-05**
- (86) Europæisk ansøgning nr.: **18883053.3**
- (86) Europæisk indleveringsdag: **2018-11-27**
- (87) Den europæiske ansøgnings publiceringsdag: **2020-10-07**
- (86) International ansøgning nr.: **US2018062624**
- (87) Internationalt publikationsnr.: **WO2019108542**
- (30) Prioritet: **2017-11-30 US 201762592503 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV
MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **SpecGx LLC, 385 Marshall Avenue, Webster Groves, Missouri 63119, USA**
- (72) Opfinder: **ORR, Brian, c/o SpecGX LLC, 385 Marshall Avenue, Webster Groves, Missouri 63119, USA**
ROESCH, Kevin, c/o SpecGX LLC, 385 Marshall Avenue, Webster Groves, Missouri 63119, USA
McCLENAGHAN, Joel, c/o SpecGX LLC, 385 Marshall Avenue, Webster Groves, Missouri 63119, USA
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**
- (54) Benævnelse: **FREMGANGSMÅDE TIL FREMSTILLING AF ACYLEREDE AMPHETAMINDERIVATER**
- (56) Fremdragne publikationer:
WO-A1-2017/003721
US-A1- 2012 157 706
US-A1- 2012 190 880

DESCRIPTION


Description

FIELD

[0001] The present disclosure generally relates to processes for preparing acetylated amphetamine derivatives and, in particular, processes for preparing L-lysine-D-amphetamine dimesylate.

BACKGROUND


[0002] L-lysine-D-amphetamine dimesylate (also called lisdexamphetamine dimesylate) is used to treat attention deficit hyperactivity disorder (ADHD) and attention deficit disorder (ADD) in adults and children 6 years of age and older. This pharmaceutical is also used to treat moderate to severe binge eating disorder (BED). It belongs to the group of medicines called central nervous system (CNS) stimulants. D-amphetamine is the active metabolite of the prodrug lisdexamphetamine dimesylate. The D-amphetamine is liberated from lisdexamphetamine enzymatically following contact with red blood cells. The conversion is rate-limited by the enzyme, which prevents high blood concentrations of D-amphetamine and reduces the abuse potential of lisdexamphetamine at clinical doses.



[0003] Processes exist for the preparation of lisdexamphetamine dimesylate at laboratory scale such as in US2012/190880 and WO 2017/003721. A need exists for a simple, inexpensive industrial process to make the latter scalable (e.g., no chromatography or rotary evaporation involved or isolation of problematic intermediates with difficult handling properties with respect to drying and recrystallization).

SUMMARY

[0004] One aspect of the present disclosure encompasses a one-pot process for preparing a compound of Formula (IV), which is an acylated amphetamine derivative. The process comprises (a) forming a reaction mixture comprising a solvent and a compound of Formula (I), the solvent being an alkyl tetrahydrofuran; (b) adding a compound of Formula (II) to the reaction mixture, thereby forming an intermediate compound of Formula (III); (c) phase extracting the reaction mixture after step (b) by sequential contact with i) a water solution, (ii) an acid solution having a pH of less than about 3, (iii) an alkaline solution having a pH of greater than about 12, and (iv) one or more additional water solutions to remove the compounds of Formulas (I) and (II) and reaction by-products, thereby forming a purified mixture comprising the intermediate compound of Formula (III); and (d) contacting the purified mixture comprising the intermediate compound of Formula (III) with an acid to form the compound of Formula (IV). The compounds of Formulas (I), (II), (III), and (IV) having the following structures:



wherein:

R is hydrocarbyl or substituted hydrocarbyl;

LG is a leaving group chosen from *N*-hydroxysuccinimidyl or halo;

PG is a protecting group; and

A is an anion.

[0005] Another aspect of the present disclosure provides a one-pot process for preparing L-lysine-D-amphetamine dimesylate. The process comprises (a) converting a D-amphetamine salt to D-amphetamine; (b) adding D-amphetamine to a reaction mixture comprising 2-methyl tetrahydrofuran and *N,N'*-di-Boc-L-lysine hydroxysuccinimide ester to form an intermediate compound, the intermediate compound being *N,N'*-di-Boc-L-lysine-o-amphetamine; (c) phase extracting the reaction mixture after step (b) by sequential contact with i) a water solution, (ii) an acid solution having a pH of less than about 3, (iii) an alkaline solution having a pH of greater than about 12, and (iv) one or more additional water solutions to remove starting reactants and reaction by-products, thereby forming a purified mixture comprising the intermediate compound; and (d) contacting the purified mixture comprising the intermediate compound with methanesulfonic acid to form L-lysine-D-amphetamine dimesylate.

[0006] Other aspects and iterations of the disclosure are described in more detail below.


DETAILED DESCRIPTION

[0007] The present disclosure provides a simplified one-pot process to prepare crude L-lysine-D-amphetamine dimesylate (lisdexamphetamine dimesylate) from D-amphetamine salts. The protected intermediate formed during the synthesis process is purified by a series of extractions (thus, eliminating the need for expensive, industrial chromatography and isolation of a problematic intermediate), dried by azeotropic distillation. No isolation is carried out until a crude lisdexamphetamine dimesylate is obtained. The crude lisdexamphetamine dimesylate is further purified by recrystallization, which includes a polishing filtration to remove any insoluble material. Cooling and isolation leads to very pure material. The process described herein has industrial applicability, with further improvements to yield (e.g., minimal isolations) and safety (e.g., elimination of toxic solvents such as 1,4-dioxane).

(I) PROCESS FOR PREPARING ACYLATED AMPHETAMINE DERIVATIVES

[0008] One aspect of the present disclosure provides a one-pot process for preparing an acylated amphetamine derivative having Formula (IV). The process comprises (a) forming a reaction mixture comprising a solvent and a compound of Formula (I), the solvent being an alkyl tetrahydrofuran; (b) adding a compound of Formula (II) to the reaction mixture, thereby forming an intermediate compound of Formula (III); (c) phase extracting the reaction mixture after step (b) by sequential contact with i) a water solution, (ii) an acid solution having a pH of less than about 3, (iii) an alkaline solution having a pH of greater than about 12, and (iv) one or more additional water solutions to remove the compounds of Formulas (I) and (II) and reaction

by-products, thereby forming a purified mixture comprising the intermediate compound of Formula (III); and (d) contacting the purified mixture comprising the intermediate compound of Formula (III) with an acid to form the compound of Formula (IV), as shown in the reaction scheme below.



wherein:

R is hydrocarbyl or substituted hydrocarbyl;

LG is a leaving group chosen from *N*-hydroxysuccinimidyl or halo;

PG is a protecting group; and

A is an anion.

[0009] The various steps of the process are detailed below.

(a) Forming a Reaction Mixture

[0010] The first step of the process comprises forming a reaction mixture comprising a compound of Formula (I) and a solvent.

(i) Compound of Formula (I)


[0011] The compound of Formula (I) comprises a carbonyl group, a leaving group (LG), an R group, and an amino group. In general, the amino group is protected with a protecting group (PG). Non-limiting examples of suitable amino protecting groups include *tert*-butyloxycarbonyl (Boc), triphenylmethyl (trityl), dimethyl-3,5-dimethoxybenzyloxycarbonyl (Ddz), 2-(4-biphenyl)isopropoxycarbonyl (Bpoc), 2-nitrophenylsulfenyl (Nps), 2-chlorobenzyloxycarbonyl (Cl-Z), or 4-methyltrityl (Mtt). In specific embodiments, the protecting group may be *tert*-butyloxycarbonyl.

[0012] In various embodiments, R in the compound of Formula (I) may be alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkylamino, substituted alkylamino, alkylhydroxy, substituted alkylhydroxy, alkylthio, substituted alkylthio, alkylaryl, or substituted alkyl aryl. In some embodiments, R may be an amino acid side chain. For example, R may be $-(CH_2)_4-NH_2$, $-(CH_2)_3-NH-C(NH)-NH_2$, $-(CH_2)_4-NH-C(NH)-NH_2$, $-CH_2-C(O)-NH_2$, $-(CH_2)_2-C(O)-NH_2$, $-CH_2-SH$, $-CH_2-OH$, $CH(OH)-CH_3$, $-CH_2-Ph-OH$, $-CH_2-C(O)-OH$, or $-(CH_2)_2-C(O)-OH$. In exemplary embodiments, R may be $-(CH_2)_4-NH_2$.

[0013] In embodiments in which R is an amino acid side chain, the terminal group of the side chain may be protected with a protecting group. Suitable amino protecting groups are listed above. Non-limiting examples suitable hydroxy protecting groups include benzoyl, β -methoxyethoxymethyl ether (MEM), methoxymethyl ether (MOM), *p*-methoxybenzyl ether (PMB), or pivaloyl.

[0014] The compound of Formula (I) also comprises a leaving group that facilitates amide coupling of the compounds of Formulas (I) and (II). The -leaving group is *N*-hydroxysuccinimidyl or halo, e.g., chloro, fluoro, or bromo.

[0015] In specific embodiments, the compound of Formula (I) is a compound of Formula (Ia):




(ii) Solvent

[0016] In general, the solvent is a solvent having limited miscibility in water. Suitable solvents include alkyl tetrahydrofuran such as 2-methyl tetrahydrofuran or 3-ethyl tetrahydrofuran. In exemplary embodiments, the solvent may be 2-methyl tetrahydrofuran.

[0017] The amount of solvent added to the reaction mixture can and will vary. In general, the weight ratio of the solvent to the compound of Formula (I) may range from about 2:1 to about 50:1. In some embodiments, the weight ratio of the solvent to the compound of Formula (I) may range from about 3:1 to about 20:1, from about 4:1 to about 20:1, from about 5:1 to about 15:1, or from about 6:1 to about 10:1.

(b) Adding a Compound of Formula (II) to the Reaction Mixture

[0018] Step (b) of the process comprises adding a compound of Formula (II) to the reaction mixture. The compound of Formula (II) is a free base of an amphetamine. In specific embodiments, the compound of Formula (II) is D-amphetamine, which is a compound of Formula (IIa):



[0019] In some embodiments, the compound of Formula (II) may be prepared from an amphetamine salt. Non-limiting examples of suitable amphetamine salts include amphetamine bitartrate, amphetamine sulfate, amphetamine aspartate, amphetamine saccharate, amphetamine hydrochloride, and amphetamine phosphate. In specific embodiments, the amphetamine salt may be amphetamine bitartrate. The amphetamine salt may be converted to the free base by contact with a base, followed by extraction with the solvent used in the process. Suitable bases include, without limit, hydroxides of alkali metals and alkaline earth metals such as, e.g., sodium hydroxide or potassium hydroxide. In exemplary embodiments, the amphetamine salt may be contacted with a hydroxide, followed by several extractions with 2-methyl tetrahydrofuran. The 2-methyl tetrahydrofuran phases (comprising the compound of Formula (II)) may be combined and added to the reaction mixture formed in step (a).

[0020] In general, the amount of the compound of Formula (II) added to the reaction mixture is about equimolar to the amount of Formula (I) present in the reaction mixture. In various embodiments, the molar ratio of the compound of Formula (II) to the compound of Formula (I) may range from about 0.8:1.0 to about 1.2:1.0, from about 0.9:1.0 to about 1.1:1.0, or from about 0.95:1.00 to about 1.05:1.00.

[0021] The reaction between the compounds of Formula (I) and Formula (II) to form the intermediate compound of Formula (II) proceeds readily at ambient or room temperature. Importantly, the reaction proceeds without the addition of an organic base or an inorganic base. The reaction mixture may be stirred and maintained at ambient or room temperature for at least about 45 minutes, at least about 2 hours, at least about 6 hours, at least 12 hours, at least about 16 hours, or at least about 24 hours.

(c) Phase Extracting the Final Reaction Mixture

[0022] Step (c) of the process comprises extracting the final reaction mixture by sequential contact with i) a water solution, (ii) an acid solution having a pH of less than about 3, (iii) an alkaline solution having a pH of greater than about 12, and (iv) one or more additional water solutions to remove the compounds of Formulas (I) and (II), remove reaction by-products (*e.g.*, the leaving group), and organic or inorganic salts, thereby forming a purified mixture comprising the intermediate compound of Formula (III). Importantly, the intermediate compound of Formula (III) is not isolated from the final reaction mixture after step (b) or the purified mixture following the phase extractions of step (c).

[0023] The phase extractions comprise sequential contact with a water solution, an acid solution having a pH of less than about 3, an alkaline solution having a pH of greater than about 12, and one or more additional water solutions. After each extraction the aqueous phase is removed and discarded. In general, the phase extractions are conducted at ambient or room temperature.

[0024] The final purified mixture comprising the alkyl tetrahydrofuran solvent and the intermediate compound of Formula (III) may be azeotropically dried at reflux until the water content of the mixture is less than about 2%, or less than about 1% by weight (Karl Fischer). The final mixture may be diluted with the same solvent used in step (a). For example, the final mixture may be diluted with the solvent until the concentration of the intermediate compound of Formula (III) ranges from about 8% to about 12% by weight. In specific embodiments, the final mixture may be diluted with 2-methyl tetrahydrofuran until the concentration of the intermediate compound of Formula (III) is about 10% by weight.

(d) Contacting the Intermediate Compound with an Acid

[0025] Step (d) of the process comprises contacting the purified mixture comprising the intermediate compound of Formula (III) with an acid to form the compound of Formula (IV). Contact with the acid removes the protecting group(s) from the intermediate compound of Formula (III) and forms an acid salt of the compound. Non-limiting examples of suitable acids include methanesulfonic acid, hydrochloric acid, oxalic acid. In specific embodiments, the acid

may be methanesulfonic acid.

[0026] The amount of acid added to the purified mixture comprising the intermediate compound of Formula (III) can and will vary. In general, the molar ratio of the acid to the intermediate compound of Formula (III) may range from about 1:1 to about 10:1. In some embodiments, the molar ratio of the acid to the intermediate compound of Formula (III) may range from about 2:1 to about 6:1, or from about 3:1 to about 4:1.

[0027] Contact with the acid is generally conducted at a temperature ranging from about 40 °C to about 70 °C. In some embodiments, the temperature may range from about 40 °C to about 50 °C, from about 50 °C to about 60 °C, or from about 60 °C to about 70 °C. In specific embodiments, contact with the acid may be conducted at about 50 °C to about 60 °C. The duration of contact with acid at the elevated temperature may proceed for at least about 4 hours, at least about 6 hours, at least about 8 hours, at least about 10 hours, or at least about 12 hours.

[0028] The mixture may then be cooled to ambient or room temperature. The compound of Formula (IV) may be isolated from the solvent/acid mixture by filtration, centrifugation, or other suitable means. In some embodiments, the compound of Formula (IV) may be isolated by filtration. The filtration may be accomplished using a Büchner funnel, a filter funnel, or other filter aid. The filtration may be gravity filtration or vacuum filtration. The filtered product may be washed with the solvent used in the process. The final product may be dried at a temperature ranging from about 50 °C to about 70 °C for about 0.5 to about 2 hours in a vacuum oven or a drying oven.

(e) Recrystallizing the Compound of Formula (IV)


[0029] In some embodiments, the process further comprises recrystallizing the compound of Formula (IV). In general, the isolated compound of Formula (IV) is mixed with a suitable solvent to form a saturated solution. Non-limiting examples of suitable solvents include isopropanol, benzene, butanol, ethanol, ethyl acetate, heptane, methanol, methyl-t-butyl ether, octane, tetrahydrofuran, toluene, combinations thereof, and mixtures of any of the foregoing and water. In some embodiments, the solvent may be a mixture of isopropanol and water. In other embodiments, the solvent may be (100%) ethanol. The temperature of the saturated solution may be increased to about 70 °C to enable a polishing filtration to remove insolubles and then cooled to about 4 °C over a period of time. The crystallized compound of Formula (IV) may be isolated by filtration. The filtered compound may be washed with the solvent used during the recrystallization process. The polished crystallized compound of Formula (IV) may be dried at a temperature ranging from about 50 °C to about 70 °C in a vacuum oven or a drying oven. The drying may proceed for at least 6 hours, at least 12 hours, at least 18 hours, or at least 24 hours.

[0030] In general, the yield of the compound of Formula (IV) prepared by the process

disclosed herein may be at least about 80%, at least about 85%, at least about 90%, or at least about 95% by weight.

(f) Exemplary Embodiment

[0031] In some embodiments, the compounds of Formulas (I), (II), (III), and (IV) are compounds of Formulas (Ia), (IIa), (IIIa), and (IV), as shown in the reaction scheme below.



(II) PROCESS FOR PREPARING L-LYSINE-D-AMPHETAMINE DIMESYLATE

[0032] Another aspect of the present disclosure encompasses a one-pot process for preparing L-lysine-D-amphetamine dimesylate (*i.e.*, the compound of Formula (IVa)). The process comprises (a) converting a D-amphetamine salt to D-amphetamine; (b) adding D-amphetamine to a reaction mixture comprising 2-methyl tetrahydrofuran (*i.e.*, 2-MeTHF) and *N,N'*-di-Boc-L-lysine hydroxysuccinimide ester (*i.e.*, a protected lysine) to form an intermediate compound, the intermediate compound being *N,N'*-di-Boc-L-lysine-D-amphetamine; (c) phase extracting the reaction mixture after step (b) with one or more aqueous solutions to remove starting reactants and reaction by-products, thereby forming a purified mixture comprising the intermediate compound; and (d) contacting the purified mixture comprising the intermediate compound with methanesulfonic acid to form L-lysine-D-amphetamine dimesylate.

[0033] Step (a) comprises contacting the D-amphetamine salt with an alkali metal or alkaline earth metal hydroxide, followed by one or more extractions with 2-methyl tetrahydrofuran. The reaction mixture of step (b) is formed by mixing the protected lysine with 2-MeTHF. The weight ratio of 2-MeTHF to the protected lysine may range from about 6:1 to about 10:1, or about 7:1. Step (b) comprises adding an approximately equimolar amount of D-amphetamine to the protected lysine. Step (b) is allowed to proceed at ambient or room temperature, during which the intermediate compound is formed.

[0034] The intermediate compound is not isolated. Rather the final reaction mixture comprising the intermediate compound is purified via a series of phase extractions during step (c). In particular, the extractions comprise sequential contact with a water solution (which removes the hydroxysuccinimide residue released from the protected lysine during the coupling reaction), an acid solution having a pH of less than about 3 (which removes the unreacted D-amphetamine and hydroxysuccinimide residues), an alkaline solution having a pH of greater than about 12 (which removes the unreacted protected lysine), and one or more additional water solutions (which remove organic and inorganic salts). After each extraction the aqueous phase is removed and discarded. The final purified mixture comprises the intermediate compound with little or no starting materials or reaction by-products.

[0035] The purified mixture comprising the intermediate compound is azeotropically dried at reflux (*e.g.*, about 80-85 °C) until the water content is less than about 1% by weight (Karl Fischer). The resulting distillate is cooled to about 50-60 °C and the concentration of the intermediate compound is adjusted to about 10% by addition of 2-MeTHF. Step (d) comprises maintaining the temperature at about 50-60 °C while adding about 3-4 equivalents of methanesulfonic acid. The temperature is maintained at about 50-60 °C for at least 6-8 hours to ensure complete deprotection of the intermediate compound and formation of L-lysine-D-amphetamine dimesylate.

[0036] The final compound is isolated by filtration, washed with 2-MeTHF, and dried. L-Lysine-D-amphetamine dimesylate is recrystallized from a mixture of isopropanol and water, and polished by washing the crystallized material with isopropanol. The crystallization step removes undesirable diastereomers, and provides highly pure L-lysine-D-amphetamine dimesylate.

DEFINITIONS

[0037] When introducing elements of the present invention or the preferred embodiments(s) thereof, the articles "a", "an", "the" and "said" are intended to mean that there are one or more of the elements. The terms "comprising", "including" and "having" are intended to be inclusive and mean that there may be additional elements other than the listed elements.

[0038] The term "about," particularly in reference to a given quantity, is meant to encompass deviations of plus or minus five percent.

EXAMPLES

[0039] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples represent techniques discovered by the inventors to function well in the practice of the invention. Those of skill in the art should, however, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments that are disclosed and still obtain a like or similar result therefore all matter set forth is to be interpreted as illustrative and not in a limiting sense.

Example 1: Preparation of D-Amphetamine Stock Solution

[0040] D-Amphetamine bitartrate (20.00 g, 0.0701 mol) was suspended in water (40.00 g). To this was added 50 wt. % sodium hydroxide (~7.25 mL) and 2-MeTHF (30 mL) to adjust aqueous phase to a pH >13. The actual pH obtained of the aqueous phase was 13.59 at 34.9 °C. The organic phase was separated and the aqueous phase was further extracted (separatory funnel) with 2-MeTHF (90 mL). The organic phases were combined and used directly in the next example, no drying was required.

Example 2: Preparation of Crude Lisdexamphetamine Dimesylate via 'One-Pot' Procedure

[0041] Di-N-Boc-L-lysine-O-Su (31.09 g, 0.0701 mol) was slurried in 2-MeTHF (160 mL) at room temperature. To this, the D-amphetamine stock solution from Example 1 was charged to

the reaction in one shot. The reaction was exothermic (e.g., the temperature rose from 20.7 °C to 29.1 °C). The reaction mixture was left to stir at room temperature for 16 hours. The reaction mixture was then quenched with water (46 mL) and the lower phase removed. The 2-MeTHF phase was further successively washed with 2 mL of concentrated hydrochloric acid in water (46 mL) (the pH of aqueous extract was < 3.00); 2 mL of 50 wt. % sodium hydroxide (the pH of extract was > 12.00); and water (46 mL) three times to remove salts. The 2-MeTHF phase remaining in the flask was set-up for azeotropic distillation using a Dean & Stark apparatus to remove water at a jacket temperature of 80-85 °C for 16 hours in this case. This removed 7.0 mL of water, the 2-MeTHF remaining typically had < 1.00 wt. % of water remaining. The reaction was then cooled to 50-60 °C and diluted with 2-MeTHF (165 mL), such that the concentration of Di-*N*-Boc-*L*-lysine-*D*-amphetamine was at 10 wt. % / v based upon 100% yield of lisdexamphetamine dimesylate (*i.e.*, 32.50 g in this example). Methanesulfonic acid (20.21 g, 0.2103 mol) was added such that the temperature was maintained between 50-60 °C; the reaction mixture was then held at this temperature to ensure complete deprotection for a least 6-8 hours. The reaction mixture was then cooled to room temperature and filtered on a Büchner funnel and washed with 2-MeTHF (50 mL). After air drying for 1 hour, the crude (30.69 g) was dried in a vacuum oven at 60 °C, 22"Hg. This afforded crude lisdexamphetamine dimesylate as a white solid (30.25 g, 94.70 % 'as-is', typically assaying at > 95 wt. %, with the excess being excess methanesulfonic acid and solvents, etc.).

Example 3: Preparation of Pure Lisdexamphetamine Dimesylate

[0042] An aliquot (20.00 g) of the crude lisdexamphetamine dimesylate from the Example 2 was recrystallized from isopropanol (160.00 g) and water (5.00 g) with a polishing filtration. Material crystallized at 63.9 °C. Left to cool to room temperature and ice cooling applied at 32.5 °C. After stirring at < 5 °C for 30 min, product was filtered and washed with isopropanol (15.00 g). This afforded a white powder friable flakes 19.31 g (96.55 % recovery). Material was oven dried overnight 60-65 °C at 0.745 bar (22"Hg) to afford the product (17.49 g, 87.45 %). Material assayed at 99.57 wt. % with no related substances present. Rolled through-put yield = $0.9470 \times 0.8755 \times 100 = 82.91 \%$.

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all

liability in this regard.

Patent documents cited in the description


- US2012190880A [0003]
- WO2017003721A [0003]

Patentkrav


1. One-pot-fremgangsmåde til fremstilling af en forbindelse af formel (IV), hvilken fremgangsmåde omfatter:

(a) dannelse af en reaktionsblanding omfattende et opløsningsmiddel og en


5 forbindelse af formel (I), idet opløsningsmidlet er en alkyl-tetrahydrofuran;



(b) tilsætning af en forbindelse af formel (II) til reaktionsblandingen, for derved at danne en mellemproduktforbindelse af formel (III);




10



(c) faseekstraktion af reaktionsblandingen efter trin (b) ved sekventiel kontakt med (i) en vandopløsning, (ii) en syreopløsning med en pH på mindre end ca. 3, (iii) en alkalisk opløsning med en pH på mere end ca. 12, og (iv) en eller flere

15 yderligere vandopløsninger for at fjerne forbindelserne af formlerne (I) og (II) og reaktions-biprodukter, for derved at danne en oprenset blanding omfattende mellemproduktforbindelsen af formel (III); og

(d) at bringe den oprensede blanding omfattende mellemproduktforbindelsen af formel (III) i kontakt med en syre for at danne forbindelsen af formel (IV);



hvor:

R er hydrocarbyl eller substitueret hydrocarbyl;

LG er en afgangsgruppe valgt fra *N*-hydroxysuccinimidyl eller halogen;

5 PG er en beskyttelsesgruppe; og

A er en anion;

hvor udtrykket "ca." omfatter afvigelser på plus eller minus fem procent.

2. Fremgangsmåden ifølge krav 1, hvor R er en aminosyresidekæde valgt fra -

- 10 (CH₂)₄-NH₂, -(CH₂)₃-NH-C(NH)-NH₂, -(CH₂)₄-NH-C(NH)-NH₂, -CH₂-C(O)-NH₂, -
 (CH₂)₂-C(O)-NH₂, -CH₂-SH, -CH₂-OH, CH(OH)-CH₃, -CH₂-Ph-OH, -CH₂-C(O)-OH
 eller -(CH₂)₂-C(O)-OH; og PG er *tert*-butoxycarbonyl, triphenylmethyl, dimethyl-
 3,5-dimethoxybenzyloxycarbonyl, 2-(4-biphenyl)isopropoxycarbonyl, 2-
 nitrophenylsulfenyl, 2-chlorobenzyloxycarbonyl eller 4-methyltriphenylmethyl.

15

3. Fremgangsmåden ifølge krav 1 eller krav 2, hvor alkyl-tetrahydrofuran og
 forbindelsen af formel (I) er til stede i reaktionsblandingen i et vægtforhold på ca.
 5:1 til ca. 15:1; hvor udtrykket "ca." omfatter afvigelser på plus eller minus fem
 procent.

20

4. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 3, hvor
 forbindelsen af formel (II) fremstillet fra et amfetaminsalt ved kontakt med en
 base, efterfulgt af en eller flere ekstraktioner med en alkyl-tetrahydrofuran.

- 25 **5.** Fremgangsmåden ifølge krav 4, hvor amfetaminsaltet er amfetamin-
 bitartrat, amfetaminsulfat, amfetaminaspartat, amfetaminsaccharat,
 amfetaminhydrochlorid eller amfetaminphosphat; og basen er et alkalimetal-
 eller jordalkalimetalhydroxid.

6. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 5, hvor alkyl-tetrahydrofuran er 2-methyl-tetrahydrofuran.

7. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 6, hvor trin (b) og
5 (c) udføres ved stuetemperatur.

8. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 7, hvor
mellemproduktforbindelsen af formel (III) eller ikke er isoleret efter trin (b) eller
trin (c).

10

9. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 8, hvor syren i trin
(d) er methansulfonsyre, saltsyre eller oxalsyre; og trin (d) udføres ved en
temperatur fra ca. 40°C til ca. 70°C; hvor udtrykket "ca." omfatter afvigelser på
plus eller minus fem procent.

15

10. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 9, yderligere
omfattende azeotropisk tørring af den oprensede blanding omfattende
mellemproduktforbindelsen af formel (III) efter trin (c), indtil den har et
vandindhold på mindre end ca. 2 vægt-%; hvor udtrykket "ca." omfatter
20 afvigelser på plus eller minus fem procent.

11. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 10, yderligere
omfattende isolering af forbindelsen af formel (IV) efter trin (d) ved filtrering.

25 **12.** Fremgangsmåden ifølge krav 11, yderligere omfattende omkrystallisering af
forbindelsen af formel (IV).


13. Fremgangsmåden ifølge krav 12, hvor omkrystalliseringen udføres i
tilstedeværelsen af en blanding af isopropanol og vand.

30


14. Fremgangsmåden ifølge krav 13, yderligere omfattende vask af den
krystalliserede forbindelse af formel (IV) med isopropanol.

15. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 14, hvor
35 forbindelsen af formel (I) er en forbindelse af formel (Ia):


4



forbindelsen af formel (II) er en forbindelse af formel (IIa):



mellemproduktforbindelsen af formel (III) er en forbindelse af formel (IIIa),



5

og forbindelsen af formel (IV) er en forbindelse af formel (IVa):

